A (HA)-modified silica nanoparticle used to co-deliver QUE and DOX was able to target CD44-overexpressing SGC7901 GC cells, inhibit the expression of Wnt16 and ABCB1, remodel the TME, and reverse MDR (92). The gene discussed is ABCB1; the disease is gastric cancer.